Fredrik Y. Frejd

3.6k total citations · 1 hit paper
76 papers, 2.8k citations indexed

About

Fredrik Y. Frejd is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Fredrik Y. Frejd has authored 76 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Radiology, Nuclear Medicine and Imaging, 35 papers in Molecular Biology and 28 papers in Oncology. Recurrent topics in Fredrik Y. Frejd's work include Monoclonal and Polyclonal Antibodies Research (59 papers), Radiopharmaceutical Chemistry and Applications (30 papers) and Glycosylation and Glycoproteins Research (25 papers). Fredrik Y. Frejd is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (59 papers), Radiopharmaceutical Chemistry and Applications (30 papers) and Glycosylation and Glycoproteins Research (25 papers). Fredrik Y. Frejd collaborates with scholars based in Sweden, United States and Russia. Fredrik Y. Frejd's co-authors include John Löfblom, Vladimir Tolmachev, Stefan Ståhl, Joachim Feldwisch, Shalom Stahl, Kyu‐Tae Kim, Anna Orlova, J. Carlsson, Torbjörn Gräslund and Per‐Åke Nygren and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Fredrik Y. Frejd

70 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications

2010 504 citations John Löfblom, Joachim Feldwisch et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fredrik Y. Frejd Sweden	28	2.0k	1.4k	975	341	240	76	2.8k
John Löfblom Sweden	29	2.1k 1.1×	1.9k 1.3×	872 0.9×	264 0.8×	235 1.0×	110	3.1k
Joachim Feldwisch Sweden	29	2.2k 1.1×	1.5k 1.0×	1.2k 1.2×	229 0.7×	360 1.5×	66	3.3k
Catarina Xavier Belgium	31	2.6k 1.3×	1.3k 0.9×	1.3k 1.4×	600 1.8×	336 1.4×	59	3.5k
Svetlana O. Doronina United States	15	2.2k 1.1×	1.4k 1.0×	2.4k 2.5×	366 1.1×	216 0.9×	27	3.8k
Joseph A. Francisco United States	12	1.8k 0.9×	1.1k 0.8×	1.9k 2.0×	415 1.2×	172 0.7×	17	3.1k
Marleen Keyaerts Belgium	30	1.9k 1.0×	1.1k 0.8×	1.4k 1.5×	769 2.3×	315 1.3×	70	3.1k
Tove Olafsen United States	30	1.6k 0.8×	947 0.7×	839 0.9×	521 1.5×	338 1.4×	69	2.7k
Johanna Lahdenranta United States	23	823 0.4×	2.0k 1.4×	1.4k 1.4×	331 1.0×	239 1.0×	51	3.6k
Susan L. Deutscher United States	30	1.4k 0.7×	2.2k 1.5×	594 0.6×	866 2.5×	270 1.1×	83	3.6k
Pamela A. Trail United States	29	1.2k 0.6×	1.7k 1.2×	1.5k 1.5×	474 1.4×	248 1.0×	61	3.7k

Countries citing papers authored by Fredrik Y. Frejd

Since Specialization

Citations

This map shows the geographic impact of Fredrik Y. Frejd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fredrik Y. Frejd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fredrik Y. Frejd more than expected).

Fields of papers citing papers by Fredrik Y. Frejd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fredrik Y. Frejd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fredrik Y. Frejd. The network helps show where Fredrik Y. Frejd may publish in the future.

Co-authorship network of co-authors of Fredrik Y. Frejd

This figure shows the co-authorship network connecting the top 25 collaborators of Fredrik Y. Frejd. A scholar is included among the top collaborators of Fredrik Y. Frejd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fredrik Y. Frejd. Fredrik Y. Frejd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hofström, Camilla, et al.. (2025). Affinity maturation and optimization of CD44v6-targeting antibodies for molecular radiotherapy. Nuclear Medicine and Biology. 144-145. 109012–109012. 1 indexed citations

Stenman, Adam, Ram Kumar Selvaraju, Hans Lundqvist, et al.. (2025). Dual-Nuclide Biodistribution and Therapeutic Evaluation of a Novel Antibody-Based Radiopharmaceutical in Anaplastic Thyroid Cancer Xenografts. Molecular Cancer Therapeutics. 24(5). 753–762. 2 indexed citations

Taylor, Peter C., Philip J. Mease, Kurt de Vlam, et al.. (2025). Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Annals of the Rheumatic Diseases. 84(6). 979–991. 2 indexed citations

Eißler, Nina, Renske Altena, Olga Bragina, et al.. (2024). Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy. Biomedicines. 12(5). 1088–1088. 12 indexed citations

Oroujeni, Maryam, Anzhelika Vorobyeva, Anna Orlova, et al.. (2024). Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile. European Journal of Nuclear Medicine and Molecular Imaging. 51(13). 4038–4048. 6 indexed citations

Altena, Renske, Emelié Karlsson, Antonios Tzortzakakis, et al.. (2024). Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [⁶⁸Ga]Ga-ABY-025: Results from a Pilot Study. Journal of Nuclear Medicine. 65(5). 700–707. 10 indexed citations

Lindman, Henrik, Per Liss, Fredrik Y. Frejd, et al.. (2024). [⁶⁸Ga]Ga-ABY-025 PET in HER2-positive breast cancer: Benefits and pitfalls in staging of axillary disease.. Journal of Clinical Oncology. 42(16_suppl). 1035–1035. 1 indexed citations

Oroujeni, Maryam, et al.. (2024). Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation. EJNMMI Radiopharmacy and Chemistry. 9(1). 30–30. 2 indexed citations

Odell, Luke R., et al.. (2024). Optimized method for fluorine-18 radiolabeling of Affibody molecules using RESCA. EJNMMI Radiopharmacy and Chemistry. 9(1). 73–73. 2 indexed citations

10.

Zhang, Bo, Johanna Rokka, Maria� Rosestedt, et al.. (2023). Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor β. EJNMMI Radiopharmacy and Chemistry. 8(1). 23–23. 10 indexed citations

11.

Oroujeni, Maryam, Tianqi Xu, Evgenii Plotnikov, et al.. (2023). Evaluation of affinity matured Affibody molecules for imaging of the immune checkpoint protein B7-H3. Nuclear Medicine and Biology. 124-125. 108384–108384. 6 indexed citations

12.

Xu, Tianqi, et al.. (2023). Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab. Cancers. 15(9). 2409–2409. 13 indexed citations

13.

Altena, Renske, Antonios Tzortzakakis, Thuy Tran, et al.. (2023). Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications. EJNMMI Research. 13(1). 43–43. 8 indexed citations

14.

Gerdes, Sascha, Petra Staubach, Thomas Dirschka, et al.. (2023). Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment. British Journal of Dermatology. 189(4). 381–391. 16 indexed citations

15.

Gudmundsdotter, Lindvi, et al.. (2023). Co-culture platform for tuning of cancer receptor density allows for evaluation of bispecific immune cell engagers. New Biotechnology. 79. 120–126. 1 indexed citations

16.

Vorobyeva, Anzhelika, Leendert J. van den Bos, Robert Naasz, et al.. (2022). Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis. Pharmaceutics. 14(11). 2519–2519. 5 indexed citations

17.

Frejd, Fredrik Y., et al.. (2018). In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor. Scientific Reports. 8(1). 5141–5141. 37 indexed citations

18.

Malm, Magdalena, Fredrik Y. Frejd, Stefan Ståhl, & John Löfblom. (2016). Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. mAbs. 8(7). 1195–1209. 39 indexed citations

19.

Lindborg, Malin, Ingmarie Höidén‐Guthenberg, Heiko Bönisch, et al.. (2014). An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. Proceedings of the National Academy of Sciences. 111(48). 17110–17115. 43 indexed citations

20.

Orlova, Anna, Andreas Jonsson, Daniel Rosik, et al.. (2013). Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein. Journal of Nuclear Medicine. 54(6). 961–968. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact